MedTrace Logo

Scalp Cooling in MBC

NCT04986579 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-11-19

No results posted yet for this study

Summary

This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab govitecan, trastuzumab deruxtecan, or eribulin.

The name of the study intervention involved in this study is:

* Paxman Scalp Cooling System

Conditions

Interventions

DEVICE

Paxman Scalp Cooling System

Cap attached to coolant lines connected to a refrigeration unit placed on scalp

DRUG

Eribulin

Intravenous Infusion

DRUG

Sacituzumab govitecan

Intravenous Infusion

DRUG

Trastuzumab deruxtecan

Intravenous Infusion

Sponsors & Collaborators

Principal Investigators

  • Elahe Salehi, DNP, ANP-BC · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-07
Primary Completion
2026-06-01
Completion
2028-06-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04986579 on ClinicalTrials.gov